ABEO
FDA Approval of Ultragenyx Gene Therapy Triggers ABEONA Royalties
Abeona is eligible for commercial milestone payments and royalties after the FDA approved FAYUVI, the Sanfilippo type A gene therapy it out-licensed in 2022.
ABEO
Market-moving news on Abeona Therapeutics (NASDAQ: ABEO): filings, earnings, deals and other events, from REDFILED.